Sequestration
Budget Cutters Propose Big Hits on Pharma
The Obama administration’s budget plan for fiscal year 2014 apparently assumes that the pharmaceutical industry can support Medicare and other health programs through changes in drug coverage and payments. It also relies on industry fees to keep the Food and Drug Administration up and running. Meanwhile, FDA and other public health agencies are contending with the sequestration mandate, which is taking another bite out of government programs and payment policies ...Read more
Advertising
Ad Agency Encourages Pharma Marketers to Reboot
At the beginning of the Reboot Camp – held at New York City’s Alexandria Center on April 12 – Intouch Solutions’ CEO Faruk Capan declared the days of Don Draper effectively over. The route to patients’ hearts and minds isn’t Old Fashioned cocktails and intuition; it’s solutions based on patient, provider and payer needs, and making disparate data streams pool around brand objectives ...Read More
CEO Compensation Data
Complete salary, bonus & market capitalization data in biotech.
www.bioworld.com
Canada
Drug Pipelines in Canada: Is There a Buyer for Future Innovation?
Last week, Canada’s National Prescription Drug Utilization Information System issued its fourth New Drug Pipeline Monitor looking at drugs currently under development that may have an impact on future drug expenditures. The report illustrates tensions between federal and provincial approaches to managing the burden of health care expenditure, which in some provinces are consuming upwards of 40% of the public budget ...Read more
Verifying Your Aggregate Spend Program and Transparency Reports
Live Webcast: Tuesday, April 30, 2013 at 11:00 am ET Register Free at:
www.pharmexec.com/aggspend
Drug Safety
Safety Trumps Access to Pain Meds for FDA
The Food and Drug Administration has come down on the side of reducing abuse of opoid medications, over encouraging wider availability of low-cost painkiller meds. The agency decided to block generic versions of the original OxyContin formulation, which is fairly easy to manipulate by illegal users ...Read more
Europe
England’s Cancer Drug Fund: An Acid Test for Value-Based Pricing
England’s Cancer Drugs Fund (CDF) could be in its final financial year, after running in full since April 2011. The fund covers the cost of cancer treatments either when NICE has said ‘no’, or hasn’t yet come to a view. Companies can’t circumvent NICE though; if a company was invited to submit to NICE and refused, it’ll be refused CDF funding for its product too. The CDF is supposed to be a ‘bridge’ to Value-Based Pricing (VBP), due to be implemented in January 2014 ...Read more
Healthcare
Physicians in ACOs Dare Pharma to Step Up Its Game
Pharma, according to physicians currently embedded within Accountable Care Organizations (ACOs), is not living up to its potential. A survey conducted by Oliver Wyman has most of its 200 respondents saying the industry could play a more active role with value-based healthcare providers in helping to deliver better care at a lower cost, but it does not and probably won’t, by most expectations ...Read more
Marketing to Professionals
Pharm Exec’s What Physician’s Want Vol. I & II
How, when and why physicians consume information. Information on marketing, detailing, sampling, prescribing, CME, conventions and meetings from some of the best in the industry. Best methods to communicate with docs. New ideas from reorganization to alternative sales channels to embedded outsourcing ...Read more
|